Q3: 2025-11-03 Earnings Summary
EPS of $0.00 beats by $0.01
| Revenue of $205.70M (-3.56% Y/Y) beats by $564.84K
Myriad Genetics, Inc. (MYGN) Q3 2025 Earnings Call November 3, 2025 4:30 PM EST
Company Participants
Matthew Scalo – Senior Vice President of Investor Relations
Samraat Raha – President, CEO & Director
Mark Verratti – Chief Operating Officer
Ben Wheeler – CFO & Principal Accounting Officer
Conference Call Participants
Puneet Souda – Leerink Partners LLC, Research Division
David Westenberg – Piper Sandler & Co., Research Division
Kyle Boucher – TD Cowen, Research Division
Lauren Timmins – Jefferies LLC, Research Division
Ricki Levitus – Guggenheim Securities, LLC, Research Division
Lu Li – UBS Investment Bank, Research Division
Benjamin Mee – Stephens Inc., Research Division
John Wilkin – Craig-Hallum Capital Group LLC, Research Division
Presentation
Operator
Good day, and thank you for standing by. Welcome to the Myriad Genetics’ Third Quarter 2025 Earnings Conference Call. [Operator Instructions] Please be advised that today’s conference is being recorded.
I would now like to hand the conference over to your first speaker today, Matt Scalo. Please go ahead.
Matthew Scalo
Senior Vice President of Investor Relations
Good afternoon, and welcome to the Myriad Genetics Third Quarter 2025 Earnings Call. During the call, we will review the financial results we released today. And afterwards, we will host a Q&A session. Our quarterly earnings release was issued this afternoon on Form 8-K and can be found on our website at investor.myriad.com.
I’m Matt Scalo, Senior Vice President of Investor Relations. On the call with me today are Sam Raha, our President and Chief Executive Officer; Ben Wheeler, our Chief Financial Officer; and Mark Verratti, our Chief Operating Officer. This call can be heard live via webcast at investor.myriad.com, and a recording will be archived in our Investors section of our website, along with this slide presentation.
Please note that some of the information presented today contains projections or other forward-looking statements regarding future events or
